Recurrence of Uveitis after Discontinuation of Infliximab. (April 2014)

• Record Type: Journal Article
• Authors: Shakoor, Akbar; Esterberg, Elizabeth; Acharya, Nisha R.
• Is Part Of: Ocular immunology and inflammation. Volume 22:Number 2(2014)
• Page Start: 96
• Page End: 101
• Publication Date: 2014-04
• Subjects: Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.3109/09273948.2013.812222
• Languages: English
• ISSNs: 0927-3948

Abstract

<abstract> <title>Abstract</title> <p> <italic>Purpose</italic>: To evaluate the recurrence of uveitis after discontinuation of infliximab once control of inflammation is achieved.</p> <p> <italic>Methods</italic>: A retrospective cohort study was conducted of patients seen at the Proctor Foundation between 1998 and 2010 who discontinued infliximab after achieving corticosteroid-sparing control by Standardization of Uveitis Nomenclature criteria. The main outcome was the proportion of patients who had a relapse of uveitis.</p> <p> <italic>Results</italic>: Eighteen patients attempted to discontinue infliximab after achieving control of inflammation, and 11 patients had a relapse. Median time to relapse was 603 days (95% CI: 85–1461 days). Patients with juvenile idiopathic arthritis (JIA)-associated uveitis (<italic>n</italic> = 4) relapsed faster (median time to relapse: 76 days, <italic>p</italic> = 0.002) compared with patients who did not have JIA-associated uveitis (median = 1169 days).</p> <p> <italic>Conclusions</italic>: The majority of patients who achieved control of inflammation on infliximab had a recurrence after discontinuing therapy. Patients with JIA experienced recurrence faster compared to other patients.</p> </abstract>